The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 09, 2006

Filed:

Aug. 14, 1997
Applicants:

Domenico Recoli, Magog, CA;

Gerard E. Plante, Sherbrooke, CA;

Fernand Gobeil, Chomedey, CA;

Witold A. Neugebauer, Ottawa, CA;

Adriana Zucollo, Buenos Aires, AR;

Orlando L. Catanzaro, Buenos Aires, AR;

Inventors:

Domenico Recoli, Magog, CA;

Gerard E. Plante, Sherbrooke, CA;

Fernand Gobeil, Chomedey, CA;

Witold A. Neugebauer, Ottawa, CA;

Adriana Zucollo, Buenos Aires, AR;

Orlando L. Catanzaro, Buenos Aires, AR;

Assignee:

Université de Sherbrooke, Sherbrooke, CA;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 49/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to novel antagonists to a B-bradykinin (B-BK) receptor which have a good affinity and selectivity therefor, some of which being at least partially resistant to enzymatic degradation. The synthesis of the Breceptors is induced during inflammation. Symptoms associated with inflammation (elevated hydrostatic pressure and plasma leakage or extravasation) have been observed in diabetic animal models (streptozotocin-induced diabetes (STZ)) as well as in spontaneously hypertensive rats (SHR). The present inventors confirm the presence of B-BK receptors in these two models. B-BK antagonists abolished the vasocontraction induced by B-BK in SHR and STZ, and reduced the glycemia of diabetic animals to normal levels. The present B-antagonists are useful for treating any condition wherein B-receptor is expressed, particularly during inflammation, and more particularly wherein B-receptor expression results in diabetic vasculopathy, other diabetic symptoms associated with an insulitis and a post-capillary resistance building as a consequence of the presence of a B-receptor.


Find Patent Forward Citations

Loading…